摘要
目的:探讨重组人血管内皮抑制素(恩度)联合化疗对肺癌的作用。方法:建立肺癌裸鼠移植模型16只,随机分为4组:空白对照组、恩度组、顺铂组、恩度联合顺铂组。治疗结束第2天处死裸鼠,测量肿瘤体积和质量,免疫组化法测微血管密度(MVD)及瘤组织血管内皮生长因子(VEGF)的表达。结果:治疗结束后,空白对照组、恩度组、顺铂组和联合组的肿瘤体积分别为(4 684.9±499.3)mm3、(3 903.4±327.4)mm3、(2 689.6±232.9)mm3和(2 007.9±317.3)mm3(P<0.05)。恩度组、顺铂组和联合组的肿瘤抑制率分别为13.5%、18.9%和35.1%(P<0.05)。免疫组化结果显示,联合组肿瘤MVD低于其他各组(P<0.05);用药组VEGF的表达与空白对照组比较有统计学差异(P<0.05)。结论:肺癌裸鼠移植瘤模型中恩度与顺铂联合抗肿瘤作用较单药明显增强,能够有效地抑制肺癌的生长。
Objective：This experiment was to identify the effect of recombinant human endostatin（endostar） combined with cisplatin（DDP） on the growth of lung cancer in nude mouse. Methods：After the establishment of the model, mice were divided into 4 groups（four in each） receiving respectively intraperitoneally for consecutive 10 or 14 days： PBS 0.2ml/d（ control group）, endostar 1.5mg/（kg·d）, DDP 1 mg/（ kg·d）, and DDP ling/（ kg· d） ＋ endostar 1.5mg/（kg·d）. Tumor volume and tumor inhibition rate （TIR） was calculated, inclding of the expression of VEGF was examined. Results ： Among four groups （ control group, endostar group, DDP group and endostar ＋ DDP group）, there was respectively （ 4 684. 9± 499. 3 ） mm^3, （ 3 903.4 ± 327.4 ） mm^3, （ 2 689. 6±232. 9 ） mm^3 and （2 007.9 ±317.3）ramz in tumor volumn（P 〈0. 05）. TIR of the endostar group, the DDP group and the endostar ＋ DDP group was respectively 13.5% , 18. 9% and 35. 1% , tumor growth of the endostar ＋ DDP group was inhibited significantly （P 〈 0.05 ）. The MVD of the endostar ＋ DDP group was also less than the other groups （ P 〈 0. 05 ）. The expression of VEGF in the YH-16 group, the DDP group and the endostar ＋ DDP group were significant difference compared to the control group （ P 〈 0. 05 ）. Condusion：Endostar in the combination with DDP has synergistic effect on inhibitory activity against the growing of lung cancer.
出处
《临床肿瘤学杂志》
CAS
2009年第5期418-420,共3页
Chinese Clinical Oncology
